Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07005947 · ClinicalTrials.gov registry record
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
A clinical trial of Long COVID-19 and Diabetic Neuropathy, sponsored by CND Life Sciences.
- Active
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT07005947: Active study of Long COVID-19 and Diabetic Neuropathy, sponsored by CND Life Sciences.
NCT07005947 is a study of Long COVID-19 and Diabetic Neuropathy that is active but no longer recruiting, run by CND Life Sciences. The registered enrollment target is 300 participants, below the 7,415-participant average among 14 other Long COVID-19 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07005947, a study of Long COVID-19 and Diabetic Neuropathy, is active but no longer recruiting, sponsored by CND Life Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.
Primary Outcome
This is a single site study of subjects with Long COVID, subject with a previous positive COVID test without persistent symptoms, and POTS subjects and diabetics. Neurocutaneous biosignatures will provide insight into the pathology and nervous system changes that occur in patients suffering from sensory and autonomic function changes.
Conditions Studied
Study Locations (1)
Arizona
- CND Life Sciences - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-11-30 |
| Est. Completion | 2026-04-16 |
What the registry record for NCT07005947 still lists
NCT07005947 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 7,415-participant average among 14 other Long COVID-19 trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Long COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT07005947 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT07005947 about?
NCT07005947 is a clinical study titled "Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project". This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.
What is the current status of trial NCT07005947?
This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2023-11-30. Estimated completion is 2026-04-16.
What conditions does trial NCT07005947 study?
This clinical trial studies the following conditions: Long COVID-19, Diabetic Neuropathy, Postural Orthostatic Tachycardia Syndrome (POTS), Acute COVID-19.
Who is sponsoring clinical trial NCT07005947?
This trial is sponsored by CND Life Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07005947 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07005947's enrollment target sits among peer trials
300 8th of 14 higher than 7 of 14 other Long COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Long COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
RECRUITING · Phase 3
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
A Study to Examine Anktiva for the Treatment of COVID-19.
RECRUITING · Phase 2
-
Long-Covid-19 Alleviation Through Learning Mindfulness Study
RECRUITING · NA
-
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECRUITING · Early Phase 1
-
The Long COVID-19 Wearable Device Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI